What would be your choice of therapy in a fit patient with relapsed CLL previously treated with bendamustine and rituximab who does not want BTK inhibitor therapy?  

I am assuming that this individual who has relapsed was receiving initial therapy with bendamustine rituximab is a young, under 65 years of age, CLL patient who does not prefer to have a BTK inhibitor. This is not an uncommon situation given the increasing knowledge of the chronic low-grade toxiciti...

For a fit patient with relapsed CLL who did not want BTK inhibitor therapy, venetoclax plus rituximab (based on Murano study) is the most effective standard of care regimen. This is a fixed 2-year duration of therapy, with 4 year PFS of about 75%. Alternative options would include a PI3K inhibitor (...